Polmacoxib
As of the edition of 20 October 2026, Polmacoxib is a small molecule: marketed, first approved in 2015 (KR); acts on CA1, CA2 and PTGS2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2015
- Kind
- Small molecule
- First approved
- 5 February 2015 (KR)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- CrystalGenomics
- Registered trials
- 7, 1 stopped early
- Disease areas
- Bones, joints and muscles
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
3 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product3 company-target rows are on route B because of Polmacoxib.
See the 3 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 4 | 3 | 0 | 1 |
| Phase 2 | 2 | 1 | 0 | 0 |
| Phase 3 | 1 | 1 | 0 | 0 |
| All trials | 7 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| CrystalGenomics | Originator and Lead sponsor of trials | 2007 to now |